|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 years and older
|
|
gptkbp:allocates
|
Randomized
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:completedIn
|
2019-12-31
|
|
gptkbp:condition
|
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
|
|
gptkbp:enrollment
|
763
|
|
gptkbp:gender
|
All
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT02915432
|
|
gptkbp:intervention
|
gptkb:Cisplatin
gptkb:Pembrolizumab
gptkb:Capecitabine
5-Fluorouracil
|
|
gptkbp:location
|
gptkb:Asia
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mask
|
Open Label
|
|
gptkbp:primaryCompletionDate
|
2019-03-31
|
|
gptkbp:result
|
Overall Survival (OS)
Progression-Free Survival (PFS)
|
|
gptkbp:sponsor
|
gptkb:Merck_Sharp_&_Dohme_LLC
|
|
gptkbp:startDate
|
2016-10-13
|
|
gptkbp:status
|
completed
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:title
|
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy Versus Chemotherapy Alone as First Line Treatment in Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-062)
|
|
gptkbp:bfsParent
|
gptkb:Toripalimab
|
|
gptkbp:bfsLayer
|
7
|